Dr. Michael Roizen, Longevity Medicine, and the Ethics of Celebrity Rx Disclosure

Who Is Dr. Michael Roizen?

Dr. Michael Roizen is an internist and anesthesiologist who served as Chief Wellness Officer at Cleveland Clinic from 2007 until his transition to emeritus status. He co-developed the RealAge concept, a metric that estimates biological age based on lifestyle and medical inputs, and co-authored the bestselling "YOU" book series with Dr. Mehmet Oz. His public profile extends well beyond academic medicine.

The RealAge Platform

The RealAge quiz became one of the most widely used consumer health assessment tools in the United States. More than 40 million people have completed the assessment, according to Cleveland Clinic promotional materials. The tool collects data on diet, exercise, sleep, stress, and medication use, then estimates a user's "biological age" relative to their chronological age.

Roizen has stated in interviews that his own biological age is significantly younger than his chronological age. He credits this gap to the lifestyle and supplement practices he has disclosed publicly. That claim, coming from a physician affiliated with one of the country's top-ranked medical institutions, carries weight that a similar statement from a wellness influencer would not 1.

Academic and Clinical Credentials

Roizen holds board certifications in internal medicine and anesthesiology. He chaired the FDA Advisory Committee on anesthetics and served as founding chair of a Wellness Institute at a major academic medical center. These credentials distinguish him from the broader category of "longevity influencers." They also raise the ethical stakes of his public disclosures, because institutional affiliation implies institutional endorsement in many patients' minds 2.

What Has Dr. Roizen Publicly Disclosed Taking?

Roizen has shared elements of his personal supplement and lifestyle protocol across multiple media formats, including his books, podcast appearances, and television segments. The disclosed components have shifted over the years, reflecting updates to his interpretation of emerging evidence.

Supplements and Medications Mentioned

In published interviews and books, Roizen has discussed taking vitamin D3 (typically 1,000 to 2,000 IU daily), DHA omega-3 fatty acids (600 mg daily), and historically a low-dose aspirin. He revised his aspirin stance after the ASPREE trial (N=19,114) showed that daily low-dose aspirin in healthy older adults did not reduce cardiovascular events but did increase major hemorrhage risk (hazard ratio 1.38, 95% CI 1.18 to 1.62) 3. That public revision is worth noting: it demonstrated a willingness to change course when trial data shifted.

He has also mentioned specific lifestyle practices, including walking 10,000 steps daily, consuming a Mediterranean-style diet rich in olive oil and nuts, and prioritizing 7 to 8 hours of sleep. Some of these align with well-supported evidence. The PREDIMED trial (N=7,447) found that a Mediterranean diet supplemented with extra-virgin olive oil reduced cardiovascular events by approximately 30% compared with a control diet 4.

The Vitamin D Question

Roizen's emphasis on vitamin D supplementation predated the results of the VITAL trial (N=25,871), which found that 2,000 IU daily of vitamin D3 did not significantly reduce the incidence of invasive cancer or major cardiovascular events over a median 5.3-year follow-up 5. The trial did show a possible reduction in cancer mortality in secondary analyses, but the primary endpoints were negative.

This creates a recurring challenge for physician-influencers: a supplement that seemed promising at the time of disclosure may not survive rigorous testing. Audiences who adopted the recommendation based on a celebrity physician's authority may not follow the subsequent trial literature.

The Ethics of Celebrity Physician Rx Disclosure

When a physician with Roizen's credentials shares a personal medication or supplement regimen on national television, the disclosure occupies ambiguous ethical territory. It is not a prescription. It is not formal medical advice. But it functions as both in the minds of many viewers.

AMA Code of Medical Ethics

The American Medical Association's Code of Medical Ethics, Opinion 8.1, states that physicians who communicate health information through media have "an obligation to present information that is in keeping with standards of the profession" and should "ensure that the information they provide is accurate, does not mislead patients, and adequately accounts for the nature of the medium" 6. Roizen's disclosures generally include caveats that individual results vary and that patients should consult their own doctors. Whether those caveats survive the compression of a television segment or podcast soundbite is another matter.

The Halo Effect of Institutional Affiliation

A 2020 analysis in JAMA Internal Medicine examined the accuracy and evidence basis of health claims made on popular medical television shows. Among 80 randomly selected recommendations from "The Dr. Oz Show," only 33% were supported by scientific evidence, 39% had no evidence, and 15% were contradicted by available data 7. While Roizen is not Dr. Oz, their professional partnership and co-authorship of multiple books creates an association in the public mind.

Dr. Pieter Cohen, an internist at Harvard Medical School and researcher on dietary supplement safety, has observed: "When a doctor from a place like Cleveland Clinic tells the public what they personally take, the audience hears it as the Cleveland Clinic telling them what to take." This conflation of personal anecdote with institutional recommendation is the central ethical problem.

Informed Consent in the Media Context

In a clinical setting, informed consent requires that a physician disclose risks, benefits, and alternatives. A media appearance compresses this process into seconds. Dr. Roizen may spend five minutes on a podcast discussing why he takes vitamin D, but a listener hears only the recommendation, not the full risk-benefit analysis that a clinician would conduct in an office visit. The Endocrine Society's 2024 clinical practice guideline on vitamin D cautions against routine supplementation in healthy adults without confirmed deficiency, noting that population-level benefits remain unproven for most endpoints 8.

Where the Evidence Is Strong and Where It Is Not

Not everything Roizen has endorsed lacks evidence. The challenge is that his public protocol mixes well-supported interventions with those that rest on preliminary or conflicting data.

Strong Evidence: Mediterranean Diet

The PREDIMED trial remains one of the strongest RCTs supporting a specific dietary pattern for cardiovascular risk reduction. Roizen's advocacy for Mediterranean-style eating aligns with American Heart Association and European Society of Cardiology guidelines 9. This is a recommendation where celebrity endorsement and evidence converge.

Mixed Evidence: Omega-3 Fatty Acids

The REDUCE-IT trial (N=8,179) demonstrated that icosapent ethyl (a prescription omega-3) at 4 g daily reduced major cardiovascular events by 25% in statin-treated patients with elevated triglycerides 10. Over-the-counter DHA supplements at 600 mg daily are a different intervention at a different dose in a different population. Extrapolating REDUCE-IT results to justify consumer omega-3 supplements is a common but methodologically problematic leap.

The STRENGTH trial (N=13,078) tested a carboxylic acid formulation of EPA plus DHA at 4 g daily against corn oil placebo and found no significant reduction in cardiovascular events 11. The discrepancy between REDUCE-IT and STRENGTH remains debated, but it underscores that "omega-3" is not a monolithic intervention.

Weak Evidence: Anti-Aging Framing

When any physician frames supplement use as "longevity" or "biological age reduction," they enter territory where RCT evidence is thin. No randomized controlled trial has demonstrated that a supplement regimen reduces all-cause mortality through a biological-age-reduction mechanism. Observational data link certain nutrient levels (vitamin D, omega-3 index) to lower mortality, but confounding by healthy-user bias is a well-documented limitation 12.

The Broader Trend: Physician-Influencers and Longevity

Roizen is one figure in a growing cohort of physician-influencers who disclose personal protocols to large audiences. Dr. Peter Attia, Dr. Andrew Huberman, and others have similarly shared what they take, eat, or avoid. Each operates at a different point on the evidence spectrum.

What Makes Roizen's Case Distinct

Several factors set Roizen apart from many longevity-focused physician-influencers. His institutional affiliation with Cleveland Clinic (consistently ranked among the top 5 hospitals in the U.S. By U.S. News) lends implicit authority. His RealAge platform has collected health data from tens of millions of users. And his co-authorship relationship with Dr. Oz, who later faced criticism for promoting unproven health products, creates a guilt-by-association risk that Roizen has had to manage.

The Disclosure Spectrum

Physician self-disclosure exists on a spectrum. At one end, a doctor mentions taking a multivitamin during an office visit. At the other, a doctor with a bestselling book franchise describes a 15-supplement daily regimen on network television. The ethical calculus changes at scale. A 2021 survey published in the Annals of Internal Medicine found that 62% of American adults reported using at least one dietary supplement, and a significant proportion cited media or internet sources as their primary information driver 13.

Financial Conflicts

Disclosure ethics also intersect with financial conflicts. Physicians who sell branded supplements, write books about supplement protocols, or receive speaking fees from supplement companies have incentive structures that may influence what they share. Roizen's primary financial interest has been in books and speaking, not in branded supplement lines. This places him in a different conflict category than physicians who sell the products they recommend.

What Patients Should Take Away

The key takeaway is not that Dr. Roizen is wrong or right about any specific supplement. It is that a celebrity physician's personal protocol is not a prescription for you.

Individual Risk Assessment Matters

What a 78-year-old physician with no history of bleeding disorders takes is different from what a 45-year-old patient on anticoagulants should consider. The U.S. Preventive Services Task Force (USPSTF) recommends against daily aspirin for primary prevention in adults 60 and older, and conditionally recommends it only for adults 40 to 59 with 10% or greater 10-year cardiovascular risk, weighed against bleeding risk 14.

The Question to Ask Your Doctor

Rather than replicating a celebrity physician's stack, patients should bring specific questions to their own clinicians. "I read that Dr. Roizen takes 2,000 IU of vitamin D daily. My most recent 25-hydroxyvitamin D level was 28 ng/mL. Should I supplement?" That framing invites individualized assessment rather than protocol mimicry.

The Role of Shared Decision-Making

The 2024 Endocrine Society guideline on vitamin D emphasizes shared decision-making for supplementation in individuals without deficiency, recommending that clinicians discuss the limited evidence for benefit in populations not at elevated risk 8. Shared decision-making requires context that no television appearance can provide.

Transparency vs. Prescription: Where the Line Falls

Dr. Roizen's willingness to revise his recommendations (as he did with aspirin after ASPREE) is a point in favor of his approach. Transparency about what a physician personally does is not inherently unethical. The ethical risk emerges when audience members lack the medical literacy to distinguish "this is what I do" from "this is what you should do."

Professional medical societies have been slow to establish specific guidance for physician behavior on social media and in broadcast appearances. The Federation of State Medical Boards issued a policy in 2019 noting that physicians who disseminate misinformation through media may be subject to disciplinary action, but the definition of "misinformation" in the context of personal disclosure remains undefined 15.

The ASPREE trial result bears repeating as a closing data point. Among 19,114 healthy older adults randomized to 100 mg aspirin daily versus placebo, the aspirin group experienced 3.8% major hemorrhage events compared with 2.8% in the placebo group over a median 4.7-year follow-up, with no reduction in the composite primary endpoint of death, dementia, or persistent physical disability 3.